Biomarker testing in NSCLC
Results of ASCEND-4 trial of ceritinib versus chemotherapy in ALK+ NSCLC patients
Gilberto De Castro Jr
Eagerly anticipated results of the FLAURA trial
Biomarkers and lung cancer: Current status
Durvalumab: the new standard of care for NSCLC?